114 related articles for article (PubMed ID: 24144850)
1. Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.
Wang YL; Lin CY; Shih KC; Huang JW; Tang CY
Bioorg Med Chem Lett; 2013 Dec; 23(23):6286-91. PubMed ID: 24144850
[TBL] [Abstract][Full Text] [Related]
2. Novel design strategy for checkpoint kinase 2 inhibitors using pharmacophore modeling, combinatorial fusion, and virtual screening.
Lin CY; Wang YL
Biomed Res Int; 2014; 2014():359494. PubMed ID: 24864236
[TBL] [Abstract][Full Text] [Related]
3. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
4. Role of CHK2 inhibitors in the cellular responses to ionizing radiation.
Zahmatkesh MH; Hosseinimehr SJ; Mahdiuni H
Mini Rev Med Chem; 2014; 14(10):812-8. PubMed ID: 25307309
[TBL] [Abstract][Full Text] [Related]
5. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
8. Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Shih KC; Lin CY; Zhou J; Chi HC; Chen TS; Wang CC; Tseng HW; Tang CY
J Chem Inf Model; 2011 Feb; 51(2):398-407. PubMed ID: 21182293
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
12. Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.
Galal SA; Khairat SHM; Ali HI; Shouman SA; Attia YM; Ali MM; Mahmoud AE; Abdel-Halim AH; Fyiad AA; Tabll A; El-Shenawy R; El Abd YS; Ramdan R; El Diwani HI
Eur J Med Chem; 2018 Jan; 144():859-873. PubMed ID: 29316526
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.
Xie HZ; Liu LY; Ren JX; Zhou JP; Zheng RL; Li LL; Yang SY
J Biomol Struct Dyn; 2011 Aug; 29(1):165-79. PubMed ID: 21696232
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
16. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening.
Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT
J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068
[TBL] [Abstract][Full Text] [Related]
17. Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates.
Galal SA; Khattab M; Shouman SA; Ramadan R; Kandil OM; Kandil OM; Tabll A; El Abd YS; El-Shenawy R; Attia YM; El-Rashedy AA; El Diwani HI
Eur J Med Chem; 2018 Feb; 146():687-708. PubMed ID: 29407991
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
